Search studies

OncoTrack study

OncoTrack attempts to address the core problems of drug-based cancer therapies: the low response rate of patients to their therapies, as well as its inevitable consequence, the low approval rates of oncology drugs. Only about 10% of cancer drug candidates entering clinical development are granted marketing authorization. Our program is based on two seminal developments: significant progress in our ability to analyze the molecular characteristics of individual tumors and patients (predominantl...

P2N ADPSOKO

PEI HUVEC-characterization study

Within a broad characterization study, we analyzed activation, viability, cytokine secretion, and permeability of human umbilical vein endothelial cells (HUVECs) upon stimulation with different stimuli. In addition HUVEC-permeability was analyzed in a trans-well-based leakage assay upon stimulation in presence or absence of human peripheral blood mononuclear cells (PBMCs).

PRECISESADS: Cross Sectional Study & Inception Cohort

The goal of this project is to use the power of OMICs, and bioinformatics to identify new classifications for diseases known to share common pathophysiological mechanisms. Such knowledge has not been applied to individual patients, depriving them of potential benefits in terms of the use of new therapeutic agents that are being developed for one disease but cannot be applied in another, due to current clinical classifications. We will investigate individuals with systemic lupus erythematosus ...

PRECISESADS: Cross Sectional Study - Lupus patients and healthy donors

Molecular Reclassification to Find Clinically Useful Biomarkers for Systemic Autoimmune Diseases: Cross Sectional Study

PRECISESADS: Mice Study - Spontaneous mouse models and genetic controls

Molecular Reclassification to Find Clinically Useful Biomarkers for Systemic Autoimmune Diseases: Mouse models

PSD-COVID19-OMICS

PSD COVID19 OMICS

Pfizer (NCT02958865)

The Pfizer UC dataset represents baseline, placebo and treatment (PF-06700841) subject and sample-level data extracted from a phase 2 study in moderate to severe ulcerative colitis.